CANCER CONTROL TRIAL BY C-MYC ANTISENSE DNA

C-MYC 反义 DNA 的癌症控制试验

• 批准号: 06671243
• 负责人: KOBAYASHI Susumu
• 金额: $ 0.64万
• 依托单位: CHIBA UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for General Scientific Research (C)
• 财政年份: 1994
• 资助国家: 日本
• 起止时间: 1994 至 1995
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-06671243/
• 关键词: c-myc; colorectal cancer; antisense oligo DNA; CIP1; WAF1; Northern blot hybridization; C‐myc

Northern blot hybridization revealed messenger RNA overexpression of c-myc gene in 85% colorectal carcinoma tissues, however, there was no overexpression for max gene. In our investigation, the antisense DNA for the translation starting locus could not depress cell growth of COLO-320 DM which derived from human colorectal cancer and had c-myc mRNA overexpression.Thereafter, we investigated the mRNA expression of CIP1/WAF1 gene which was cycline dependent kinase (CDK) inhibitor in colorectal carcinoma to detect more important cell growth genes. The expression in tumor tissues were depressed in all 16 case compared with the correspondent nontumor tissues. We also detect the p53 gene mutation through the PCR-SSCP method for the correpondent DNA.We could identified 6 mutation cases in 16 cases. These mutant cases indicated the more depressed mRNA expression compared with wilds p53 cases. These result indicated that there could be the possibility for more useful therapy through CIP1/WAF1 gene control

北方杂交显示85%的大肠癌组织中c-myc基因RNA过表达，而max基因RNA无过表达。本研究中，翻译起始位点的反义DNA不能抑制c-myc mRNA过表达的人结直肠癌科洛-320 DM细胞的生长，因此，我们研究了细胞周期蛋白依赖性激酶（cycline dependent kinase，CDK）抑制剂CIP 1/WAF 1基因在结直肠癌中的mRNA表达，以检测更重要的细胞生长基因。16例肿瘤组织中的表达均低于相应的非肿瘤组织。同时对相应的DNA进行PCR-SSCP检测，发现16例中有6例p53基因突变。与野生型p53相比，突变型p53基因mRNA表达水平降低。这些结果表明，通过CIP 1/WAF 1基因调控，有可能获得更有效的治疗